How I treat non-transfusion-dependent β-thalassemia

被引:12
|
作者
Saliba, Antoine N. [1 ]
Musallam, Khaled M. [2 ]
Taher, Ali T. [3 ,4 ]
机构
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Burjeel Med City, Thalassemia Ctr, Abu Dhabi, U Arab Emirates
[3] Amer Univ, Beirut Med Ctr, Dept Internal Med, Beirut, Lebanon
[4] Amer Univ, Beirut Med Ctr, Dept Internal Med, POB 11-0236, Beirut 11072020, Lebanon
关键词
PULMONARY ARTERIAL-HYPERTENSION; LIVER IRON CONCENTRATION; INEFFECTIVE ERYTHROPOIESIS; SERUM FERRITIN; RISK-FACTORS; INTERMEDIA; SPLENECTOMY; HYDROXYUREA; MANAGEMENT; OVERLOAD;
D O I
10.1182/blood.2023020683
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The intricate interplay of anemia and iron overload under the pathophysiological umbrella of ineffective erythropoiesis in non-transfusion-dependent beta-thalassemia (NTDT) results in a complex variety of clinical phenotypes that are challenging to diagnose and manage. In this article, we use a clinical framework rooted in pathophysiology to present 4 common scenarios of patients with NTDT. Starting from practical considerations in the diagnosis of NTDT, we delineate our strategy for the longitudinal care of patients who exhibit different constellations of symptoms and complications. We highlight the use of transfusion therapy and novel agents, such as luspatercept, in the patient with anemia-related complications. We also describe our approach to chelation therapy in the patient with iron overload. Although tackling every specific complication of NTDT is beyond the scope of this article, we touch on the management of the various morbidities and multisystem manifestations of the disease.
引用
收藏
页码:949 / 960
页数:12
相关论文
共 50 条
  • [41] The long-term and extensive efficacy of low dose thalidomide in a case of an untransfusable patient with Non-Transfusion-Dependent Thalassemia
    Ricchi, Paolo
    Costantini, Silvia
    Spasiano, Anna
    De Dominicis, Gianfranco
    Di Matola, Tiziana
    Cinque, Patrizia
    Ammirabile, Massimiliano
    Marsella, Maria
    Filosa, Aldo
    BLOOD CELLS MOLECULES AND DISEASES, 2016, 57 : 97 - 99
  • [42] Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience
    Karimi, Mehran
    Zarei, Tahereh
    Bahmanimehr, Ardeshir
    Aramesh, Azam
    Daryanoush, Saeed
    Haghpanah, Sezaneh
    ANNALS OF HEMATOLOGY, 2021, 100 (12) : 2901 - 2907
  • [43] Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition
    Viprakasit, Vip
    Tyan, Paul
    Rodmai, Sarayuth
    Taher, Ali T.
    ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [44] Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
    Taher, Ali T.
    Porter, John B.
    Viprakasit, Vip
    Kattamis, Antonis
    Chuncharunee, Suporn
    Sutcharitchan, Pranee
    Siritanaratkul, Noppadol
    Galanello, Renzo
    Karakas, Zeynep
    Lawniczek, Tomasz
    Habr, Dany
    Ros, Jacqueline
    Zhang, Yiyun
    Cappellini, M. Domenica
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (06) : 503 - 506
  • [45] Long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia: a comprehensive single-center experience
    Mehran Karimi
    Tahereh Zarei
    Ardeshir Bahmanimehr
    Azam Aramesh
    Saeed Daryanoush
    Sezaneh Haghpanah
    Annals of Hematology, 2021, 100 : 2901 - 2907
  • [46] PlGF and sFlt-1 levels in patients with non-transfusion-dependent thalassemia: Correlations with markers of iron burden and endothelial dysfunction
    Kelaidi, Charikleia
    Kattamis, Antonis
    Apostolakou, Filia
    Poziopoulos, Christos
    Lazaropoulou, Christina
    Delaporta, Polyxeni
    Kanavaki, Ino
    Papassotiriou, Ioannis
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (06) : 630 - 635
  • [47] Evaluation of cardiac complications in transfusion-dependent thalassemia (TDT) and non-transfusion dependent thalassemia (NTDT) beta thalassemia patients
    Nameq, Marah Sudad
    Shamoon, Rawand P.
    Saka, Mariwan H.
    IRAQI JOURNAL OF HEMATOLOGY, 2020, 9 (01) : 11 - 16
  • [48] Meta-analysis on effectiveness of hydroxyurea to treat transfusion-dependent beta-thalassemia
    Bayanzay, Karim
    Khan, Ramsha
    HEMATOLOGY, 2015, 20 (08) : 469 - 476
  • [49] Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions
    Porter, John B.
    Cappellini, Maria Domenica
    Kattamis, Antonis
    Viprakasit, Vip
    Musallam, Khaled M.
    Zhu, Zewen
    Taher, Ali T.
    BRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (02) : 288 - 299
  • [50] Deferasirox: an orphan drug for chronic iron overload in non-transfusion dependent thalassemia syndromes
    Halawi, Racha
    Motta, Irene
    Taher, Ali
    Cappellini, Maria Domenica
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (06): : 677 - 686